IP Library Patent Application 13937605
Patent Application
App. No. 13/937,605

Topical Formulations Comprising DNA Repair Enzymes, and Methods of Use Thereof

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/937,605
Abstract

Disclosed are methods of decreasing or preventing UV-induced skin damage, comprising the step of applying to an area of skin an effective amount of a topical formulation comprising a photolyase and an endonuclease. In certain embodiments, the formulation is applied before and after UV exposure.

Claims (470)

1 . A topical formulation, comprising a photolyase; an endonuclease; and a dermatologically acceptable carrier or excipient.

2 . The topical formulation of claim 1 , wherein the photolyase is from A. nidulans.

3 . The topical formulation of claim 1 , wherein the endonuclease is from M. luteus.

4 . The topical formulation of claim 1 , wherein the photolyase is from A. nidulans ; and the endonuclease is from M. luteus.

5 . The topical formulation of claim 1 , wherein the topical formulation consists essentially of

% by weight of the

Ingredient

topical formulation

a diluent

from about 35 to about 95

a humectant or a solvent

from about 5 to about 15

a skin conditioning agent or an emollient

from about 4 to about 12

a DNA repair enzyme

from about 1.5 to about 4.5

a suspending agent

from about 0.1 to about 2

an emulsion stabilizer, an emulsifier, or

from about 2.5 to about 7.5

a surfactant

an antioxidant

from about 0.5 to about 1.5

a chelating agent

from about 0.05 to about 0.15

a preservative

from about 0.4 to about 1.2

a pH adjuster

6 . The topical formulation of claim 1 , wherein the topical formulation consists essentially of

% by weight of the

Ingredient

topical formulation

Water

from about 35 to about 95

Glycerin

from about 3 to about 11

Ethylhexyl Palmitate

from about 2 to about 6

Cetearyl Alcohol

from about 1 to about 3

Propylene Glycol

from about 1 to about 4

Dicetyl Phosphate

from about 0.5 to about 2.5

Theobroma Grandiflorum Seed Butter

from about 1 to about 3

Petrolatum

from about 0.5 to about 1.5

Dimethicone

from about 0.5 to about 1.5

A. nidulans Extract

from about 0.5 to about 1.5

Arabidopsis Thaliana Extract

from about 0.5 to about 1.5

Micrococcus Luteus Lysate

from about 0.5 to about 1.5

Lecithin

from about 0.5 to about 1.5

Ceteareth-10 Phosphate

from about 0.3 to about 0.9

Steareth-10

from about 0.3 to about 0.9

Hydroxypropyl Bispalmitamide MEA

from about 0.2 to about 0.8

(Ceramide)

Tocopheryl Acetate

from about 0.5 to about 1.5

Disodium EDTA

from about 0.05 to about 0.15

Phenoxyethanol

from about 0.4 to about 1.2

Sodium Hyaluronate

from about 0.05 to about 0.15

Sodium Hydroxide

7 . The topical formulation of claim 1 , wherein the topical formulation consists essentially of

% by weight of

Ingredient

topical formulation

Water

about 71.64

Glycerin

about 7.50

Ethylhexyl Palmitate

about 4.00

Cetearyl Alcohol

about 2.00

Propylene Glycol

about 2.50

Dicetyl Phosphate

about 1.40

Theobroma Grandiflorum Seed Butter

about 2.00

Petrolatum

about 1.00

Dimethicone

about 1.00

A. nidulans Extract

about 1

Arabidopsis Thaliana Extract

about 1

Micrococcus Luteus Lysate

about 1

Lecithin

about 1

Ceteareth-10 Phosphate

about 0.60

Steareth-10

about 0.86

Hydroxypropyl Bispalmitamide MEA

about 0.50

(Ceramide)

Tocopheryl Acetate

about 1.00

Disodium EDTA

about 0.10

Phenoxyethanol

about 0.80

Sodium Hyaluronate

about 0.10

Sodium Hydroxide

8 . The topical formulation of claim 1 , wherein the topical formulation consists essentially of

% by weight of the

Ingredient

topical formulation

a diluent

from about 45 to about 95

a thickener

from about 0.25 to about 0.8

a humectant or a solvent

from about 4 to about 12

an anti-irritant

from about 0.5 to about 1.5

a DNA repair enzyme

from about 1.5 to about 4.5

a suspending agent

from about 0.5 to about 1.5

an emollient

from about 3 to about 9

a chelating agent

from about 0.05 to about 0.15

a preservative

from about 0.5 to about 1.5

pH Adjuster

9 . The topical formulation of claim 1 , wherein the topical formulation consists essentially of

% by weight of the

Ingredient

topical formulation

Water

from about 45 to about 95

Carbomer 980

from about 0.1 to about 0.6

Acrylates/C10-C30 Alkyl Acrylate

from about 0.1 to about 0.3

Crosspolymer

Glycerin

from about 1.5 to about 4.5

Propanediol

from about 1.5 to about 4.5

Disodium EDTA

from about 0.05 to about 0.15

Sodium Hyaluronate

from about 1 to about 3

Evodia Rutaecarpia Fruit Extract

from about 0.5 to about 1.5

A. nidulans Extract

from about 0.5 to about 1.5

Arabidopsis Thaliana Extract

from about 0.5 to about 1.5

Micrococcus Luteus Lysate

from about 0.5 to about 1.5

Lecithin

from about 0.5 to about 1.5

Ethylhexyl Isononanoate

from about 2.50

Isononyl Isononanoate

from about 2.50

Butylene Glycol

from about 0.0001

BHT

from about <1%

Ergothioneine

from about 0.0001

Santalam Album (Sandalwood) Extract

from about 0.33

Phellodendron Amurense Bark Extract

from about 0.33

Hordeum Distichon (Barley) Extract

from about 0.33

Sodium Hydroxide

10 . The topical formulation of claim 1 , wherein the topical formulation consists essentially of

%, by weight of the

Ingredient

topical formulation

Water

about 85.85

Carbomer 980

about 0.35

Acrylates/C10-C30 Alkyl Acrylate

about 0.20

Crosspolymer

Glycerin

about 3.00

Propanediol

about 3.00

Disodium EDTA

about 0.10

Sodium Hyaluronate

about 2.00

Evodia Rutaecarpia Fruit Extract

about 1

A. nidulans Extract

about 1

Arabidopsis Thaliana Extract

about 1

Micrococcus Luteus Lysate

about 1

Lecithin

about 1

Ethylhexyl Isononanoate

about 2.50

Isononyl Isononanoate

about 2.50

Butylene Glycol

about 0.0001

Butylated hydroxy toluene (BHT)

about 1

Ergothioneine

about 0.0001

Santalam Album (Sandalwood) Extract

about 0.33

Phellodendron Amurense Bark Extract

about 0.33

Hordeum Distichon (Barley) Extract

about 0.33

Sodium Hydroxide

11 . A method of decreasing or preventing UV-induced skin damage, comprising the step of applying to an area of skin an effective amount of a topical formulation comprising a photolyase; an endonuclease; and a dermatologically acceptable carrier or excipient.

12 . The method of claim 11 , wherein the photolyase is from A. nidulans.

13 . The method of claim 11 , wherein the endonuclease is from M. luteus.

14 . The method of claim 11 , wherein the photolyase is from A. nidulans ; and the endonuclease is from M. luteus.

15 . The method of claim 11 , wherein the topical formulation consists essentially of

% by weight of the

Ingredient

topical formulation

a diluent

from about 35 to about 95

a humectant or a solvent

from about 5 to about 15

a skin conditioning agent or an emollient

from about 4 to about 12

a DNA repair enzyme

from about 1.5 to about 4.5

a suspending agent

from about 0.1 to about 2

an emulsion stabilizer, an emulsifier, or

from about 2.5 to about 7.5

a surfactant

an antioxidant

from about 0.5 to about 1.5

a chelating agent

from about 0.05 to about 0.15

a preservative

from about 0.4 to about 1.2

a pH adjuster

16 . The method of claim 11 , wherein the topical formulation consists essentially of

% by weight of the

Ingredient

topical formulation

Water

from about 35 to about 95

Glycerin

from about 3 to about 11

Ethylhexyl Palmitate

from about 2 to about 6

Cetearyl Alcohol

from about 1 to about 3

Propylene Glycol

from about 1 to about 4

Dicetyl Phosphate

from about 0.5 to about 2.5

Theobroma Grandiflorum Seed Butter

from about 1 to about 3

Petrolatum

from about 0.5 to about 1.5

Dimethicone

from about 0.5 to about 1.5

A. nidulans Extract

from about 0.5 to about 1.5

Arabidopsis Thaliana Extract

from about 0.5 to about 1.5

Micrococcus Luteus Lysate

from about 0.5 to about 1.5

Lecithin

from about 0.5 to about 1.5

Ceteareth-10 Phosphate

from about 0.3 to about 0.9

Steareth-10

from about 0.3 to about 0.9

Hydroxypropyl Bispalmitamide MEA

from about 0.2 to about 0.8

(Ceramide)

Tocopheryl Acetate

from about 0.5 to about 1.5

Disodium EDTA

from about 0.05 to about 0.15

Phenoxyethanol

from about 0.4 to about 1.2

Sodium Hyaluronate

from about 0.05 to about 0.15

Sodium Hydroxide

17 . The method of claim 11 , wherein the topical formulation consists essentially of

% by weight of the

Ingredient

topical formulation

Water

about 71.64

Glycerin

about 7.50

Ethylhexyl Palmitate

about 4.00

Cetearyl Alcohol

about 2.00

Propylene Glycol

about 2.50

Dicetyl Phosphate

about 1.40

Theobroma Grandiflorum Seed Butter

about 2.00

Petrolatum

about 1.00

Dimethicone

about 1.00

A. nidulans Extract

about 1

Arabidopsis Thaliana Extract

about 1

Micrococcus Luteus Lysate

about 1

Lecithin

about 1

Ceteareth-10 Phosphate

about 0.60

Steareth-10

about 0.86

Hydroxypropyl Bispalmitamide MEA

about 0.50

(Ceramide)

Tocopheryl Acetate

about 1.00

Disodium EDTA

about 0.10

Phenoxyethanol

about 0.80

Sodium Hyaluronate

about 0.10

Sodium Hydroxide

18 . The method of claim 11 , wherein the topical formulation consists essentially of

% by weight of the

Ingredient

topical formulation

a diluent

from about 45 to about 95

a thickener

from about 0.25 to about 0.8

a humectant or a solvent

from about 4 to about 12

an anti-irritant

from about 0.5 to about 1.5

a DNA repair enzyme

from about 1.5 to about 4.5

a suspending agent

from about 0.5 to about 1.5

an emollient

from about 3 to about 9

a chelating agent

from about 0.05 to about 0.15

a preservative

from about 0.5 to about 1.5

pH Adjuster

19 . The method of claim 11 , wherein the topical formulation consists essentially of

% by weight of the

Ingredient

topical formulation

Water

from about 45 to about 95

Carbomer 980

from about 0.1 to about 0.6

Acrylates/C10-C30 Alkyl Acrylate

from about 0.1 to about 0.3

Crosspolymer

Glycerin

from about 1.5 to about 4.5

Propanediol

from about 1.5 to about 4.5

Disodium EDTA

from about 0.05 to about 0.15

Sodium Hyaluronate

from about 1 to about 3

Evodia Rutaecarpia Fruit Extract

from about 0.5 to about 1.5

A. nidulans Extract

from about 0.5 to about 1.5

Arabidopsis Thaliana Extract

from about 0.5 to about 1.5

Micrococcus Luteus Lysate

from about 0.5 to about 1.5

Lecithin

from about 0.5 to about 1.5

Ethylhexyl Isononanoate

from about 2.50

Isononyl Isononanoate

from about 2.50

Butylene Glycol

from about 0.0001

BHT

from about <1%

Ergothioneine

from about 0.0001

Santalam Album (Sandalwood) Extract

from about 0.33

Phellodendron Amurense Bark Extract

from about 0.33

Hordeum Distichon (Barley) Extract

from about 0.33

Sodium Hydroxide

20 . The method of claim 11 , wherein the topical formulation consists essentially of

%, by weight of the

Ingredient

topical formulation

Water

about 85.85

Carbomer 980

about 0.35

Acrylates/C10-C30 Alkyl Acrylate

about 0.20

Crosspolymer

Glycerin

about 3.00

Propanediol

about 3.00

Disodium EDTA

about 0.10

Sodium Hyaluronate

about 2.00

Evodia Rutaecarpia Fruit Extract

about 1

A. nidulans Extract

about 1

Arabidopsis Thaliana Extract

about 1

Micrococcus Luteus Lysate

about 1

Lecithin

about 1

Ethylhexyl Isononanoate

about 2.50

Isononyl Isononanoate

about 2.50

Butylene Glycol

about 0.0001

Butylated hydroxy toluene (BHT)

about 1

Ergothioneine

about 0.0001

Santalam Album (Sandalwood) Extract

about 0.33

Phellodendron Amurense Bark Extract

about 0.33

Hordeum Distichon (Barley) Extract

about 0.33

Sodium Hydroxide

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY AGREEMENT Recorded Jul 6, 2015
From: ECR PHARMACEUTICALS CO., INC.; PRECISION DERMATOLOGY, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 036091/0257 →
RELEASE OF SECURITY INTEREST Recorded Jul 7, 2014
From: GCI CAPITAL MARKETS, LLC
To: PRECISION DERMATOLOGY, INC.
Reel/Frame 033280/0556 →
SECURITY AGREEMENT Recorded Sep 20, 2013
From: PRECISION DERMATOLOGY, INC.
To: GCI CAPITAL MARKETS LLC
Reel/Frame 031249/0011 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2013
From: TRUMBORE, MARK W.; STIMSON, DRAKE D.; SOWYRDA, PAUL
To: PRECISION DERMATOLOGY, INC.
Reel/Frame 031265/0557 →